Botanix Pharmaceuticals Limited (AU:BOT)
ASX:BOT
Want to see AU:BOT full AI Analyst Report?
BOT Stock Chart & Stats
AU$0.04
>-AU$0.01(-1.09%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-1.09%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.35
Previous CloseN/A
Volume8.15M
Average Volume (3M)8.47M
Market Cap
AU$57.42M
Enterprise ValueAU$46.88M
Total Cash (Recent Filing)AU$31.61M
Total Debt (Recent Filing)AU$30.67M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 28, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding2,734,312,700
10 Day Avg. Volume7,344,780
30 Day Avg. Volume8,473,310
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.26
Price to Sales (P/S)101.98
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.57Price Target Upside1325.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$34.99M
Bulls Say, Bears Say
Bulls Say
Rapid Prescription And Revenue RampSustained, large percentage increases in prescriptions and net revenue indicate durable commercial adoption and early product-market fit. If prescription momentum and payer coverage persist, revenue can scale materially without equivalent R&D spend, improving unit economics over the next 2–6 months and beyond.
Scalable Fulfillment Platform (SendRx)A high-performing, scalable fulfillment platform reduces friction to patient access and improves gross-to-net realization. Structural advantages in reimbursement and refill rates can sustain higher lifetime value per patient and enable efficient roll-out of new indications or products without proportionate increases in SG&A.
Long IP Runway And Large Addressable MarketPatent protection to 2040 and a multi-million patient TAM create a long commercial runway and optionality for sustained revenues or strategic transactions. Durable exclusivity supports pricing power, potential margin expansion as scale increases, and long-term value capture for launch investment.
Bears Say
Very High Cash BurnProfound negative operating and free cash flow reflects a structural funding requirement to sustain commercial and manufacturing scale. Persistent cash burn increases dilution risk, forces prioritization of spend, and constrains strategic options if revenue growth or margin improvement stalls over the next several quarters.
Single-source API And Purchase ObligationsDependence on one API supplier with fixed purchase schedules is a structural supply-chain vulnerability. Qualification of an alternate supplier takes months and capital; any disruption or delay could impede manufacturing, raise COGS, or stall revenue scaling until redundancy is established.
Partially Funded Capital Raise And Financing RiskA large, contingent capital raise leaves funding execution uncertain despite strong commercial traction. With limited cash on hand versus material near-term obligations, failure or delay in securing the full raise could force cutbacks, postpone supplier qualification or trigger dilutive financings, hindering strategic plans.
Botanix Pharmaceuticals Limited News
BOT FAQ
What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
Botanix Pharmaceuticals Limited lowest share price was AU$0.02 and its highest was AU$0.35 in the past 12 months.
What is Botanix Pharmaceuticals Limited’s market cap?
Botanix Pharmaceuticals Limited’s market cap is AU$57.42M.
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
Botanix Pharmaceuticals Limited’s upcoming earnings report date is Aug 28, 2026 which is in 76 days.
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Botanix Pharmaceuticals Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.007.
Is Botanix Pharmaceuticals Limited overvalued?
According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued.
Does Botanix Pharmaceuticals Limited pay dividends?
Botanix Pharmaceuticals Limited does not currently pay dividends.
What is Botanix Pharmaceuticals Limited’s EPS estimate?
Botanix Pharmaceuticals Limited’s EPS estimate is -0.01.
How many shares outstanding does Botanix Pharmaceuticals Limited have?
Botanix Pharmaceuticals Limited has 2,734,312,700 shares outstanding.
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Botanix Pharmaceuticals Limited reported an EPS of -AU$0.017 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:BOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Botanix Pharmaceuticals Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.57 (1325.00% Upside)
AU$0.57 (1325.00% Upside)
Blogger Sentiment
Bullish
AU:BOT Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$450.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.57%
12-Months-Change
Fundamentals
Return on Equity
-131.13%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
BOT Stock 12 Month Forecast
Average Price Target
AU$0.57
▲(1325.00% Upside)
Technical Analysis
Options Prices
Currently, No data available
---